TetraKit

Next Generation Theranostics

circles design
molecules

TetraKit: Next Generation Theranostics

Targeted radionuclide therapy is an emerging field that has shown great promise in the treatment of late-stage metastatic cancer. Theranostics combines radionuclide therapy with diagnosis by nuclear imaging. In theranostics, cancer-targeting molecules, known as radiopharmaceuticals, carry radioactive atoms specifically to tumors. Depending on which type of radiation is chosen, physicians can either diagnose the severity and spread of the cancer or treat it by selectively destroying the cancerous tissue. TetraKit is a new, click chemistry based radiochemical platform, which allows for labeling of virtually any cancer-targeting molecule with any radionuclide pair for theranostics. TetraKit Technologies focuses its development program on fluorine-18 and astatine-211 as this pair is the best suited radionuclide pair for PET imaging and targeted alpha-radionuclide therapy. Alpha-therapy has attracted wide interest in current oncology as it succeeded where conventional therapies failed. TetraKit will develop the next generation of theranostic radiopharmaceuticals, which will improve patient care and disease outcomes.

Logo transparent

Latest news

from TetraKit Technologies

September 12, 2023

Highlight lecture

Today at #EANM23 in Vienna, Dr. Umberto Battisti presented our data and findings as an EANM-highlighted lecture. We are grateful for the opportunity to show our data to the scientific community dedicated to this field.
Please reach out if you want to hear more about our platform technology.
#Radiotheranostics #TetraKitTechnologies

Read more

September 9, 2023

Highlight at EANM 23

Thank you European Association of Nuclear Medicine (EANM) for choosing our talk as a highlight session for this year.

You are invited to the Tuesday morning session, where Dr. Umberto Maria Battisti will present our universal labeling platform and its application to develop radiopharmaceuticals labeled with 18F and 211At.

The talk will take place on Tuesday, September 12th, from 09:45 to 11:15 at the M2M Track.

We hope to see you there.
#eanm23

Read more

September 7, 2023

EANM 23

We are pleased to announce that Dr. Umberto Maria Battisti, the COO and co-founder of TetraKit Technologies, will be speaking at the European Association of Nuclear Medicine (EANM) 23. During the speech, he will highlight the inventive application of our platform in creating next-generation theranostics with the use of 211At.
We are excited to have you join us on this special occasion.
#eanm23 

Read more

Message from the CEO

Andreas Jensen, PhD

Andreas Jensen, PhD

Chief Executive Officer

Message from the CEO

“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”

Message from the CSO

Matthias Herth, PhD

Matthias Herth, PhD

Chief Scientific Officer

Message from the CSO

“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”